Omezax-D Capsule is a combination pharmaceutical formulation containing Domperidone 10mg and Omeprazole 20mg, designed to manage gastrointestinal disorders characterized by acid reflux, indigestion, and delayed gastric emptying. Omeprazole, a proton pump inhibitor, effectively suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby providing symptomatic relief in conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying without affecting central dopamine receptors, reducing symptoms of nausea, vomiting, bloating, and discomfort associated with delayed gastric emptying and gastroparesis. The synergistic action of these two active ingredients in Omezax-D Capsule offers comprehensive management by both reducing acid secretion and enhancing gastrointestinal motility. This combination is particularly beneficial in patients requiring acid suppression along with prokinetic therapy. Omezax-D should be used under medical supervision, with caution in patients with cardiac disorders due to the potential risk of QT interval prolongation associated with Domperidone. It is contraindicated in individuals with known hypersensitivity to either component and should be administered as per prescribed dosage to optimize therapeutic outcomes and minimize adverse effects.